Loading news...
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs.
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja.
FDA issued a CRL to Pharming's Joenja child use filing, citing dosing concerns in lower-weight kids and testing issues.
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raised an issue with the potential for underexposure in lower weight pediatric patients.
Pharming Group (NASDAQ: PHAR - Get Free Report) and Adlai Nortye (NASDAQ: ANL - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Insider and Institutional Ownership 0.0% of Pharming
Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report)'s stock price gapped down prior to trading on Friday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock had previously closed at $17.67, but opened at $17.06. Pharming Group shares last traded at $17.0210, with a volume of
Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report)'s share price was up 4.4% on Wednesday. The stock traded as high as $17.32 and last traded at $17.55. Approximately 5,296 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 10,425 shares. The stock had previously closed
Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $18.20 and last traded at $18.1050, with a volume of 1567 shares trading hands. The stock had previously closed at $18.09. Analyst Upgrades and Downgrades PHAR has been
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Dec. 22:
The mean of analysts' price targets for Pharming Group (PHAR) points to an 81.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The mean of analysts' price targets for Pharming Group (PHAR) points to a 100.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pharming Group N.V. ( PHAR ) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas Anurag Relan - Chief Medical Officer Kenneth Lynard - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Natalia Webster - RBC Capital Markets, Research Division Simon Scholes - First Berlin Equity Research GmbH Presentation Operator Good day, and thank you for standing by.